Boston Scientific/$BSX
1D1W1MYTD1Y5YMAX
Capital at risk
About Boston Scientific
Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
- Ticker
- $BSX
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 59,000
- Headquarters
- Marlborough, United States
- Website
- www.bostonscientific.com
BSX Metrics
BasicAdvanced
$69B
19.37
$2.47
0.57
-
Price and volume
Market cap
$69B
Beta
0.57
52-week high
$109.50
52-week low
$42.20
Average daily volume
20M
Financial strength
Current ratio
1.24
Quick ratio
0.558
Long term debt to equity
43.362
Total debt to equity
42.25
Interest coverage (TTM)
11.84%
Profitability
EBITDA (TTM)
5,711
Gross margin (TTM)
69.19%
Net profit margin (TTM)
17.50%
Operating margin (TTM)
20.47%
Effective tax rate (TTM)
5.00%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
6.19%
Return on equity (TTM)
15.34%
Valuation
Price to earnings (TTM)
19.368
Price to revenue (TTM)
3.369
Price to book
2.77
Price to tangible book (TTM)
265.09
Price to free cash flow (TTM)
19.515
Free cash flow yield (TTM)
5.12%
Free cash flow per share (TTM)
2.449
Growth
Revenue change (TTM)
13.53%
Earnings per share change (TTM)
46.89%
3-year revenue growth (CAGR)
16.15%
10-year revenue growth (CAGR)
10.30%
3-year earnings per share growth (CAGR)
60.29%
10-year earnings per share growth (CAGR)
25.45%
What the Analysts think about BSX
Analyst ratings (Buy, Hold, Sell) for Boston Scientific stock.
Analyst projections of the future price of Boston Scientific stock.
Bulls say / Bears say
Boston Scientific’s Q2 2026 adjusted EPS of $0.86 beat the consensus of $0.83 and its revenue of $5.44 billion topped the $5.37 billion forecast, underscoring strong operational execution across its MedSurg and Cardiovascular segments. (Reuters)
The company executed a $2 billion accelerated share repurchase agreement, expected to add $0.02 to its 2026 adjusted EPS, demonstrating management’s commitment to shareholder returns and effective capital allocation. (Reuters)
On March 30, 2026, Boston Scientific received FDA 510(k) clearance for its Asurys Fluid Management System, expanding its urology portfolio and positioning it to capture growth in high-volume endoscopic procedures. (Reuters)
Boston Scientific cut its 2026 adjusted EPS guidance to $3.28–$3.32 per share from a prior range of $3.34–$3.41, reflecting softer demand for its Watchman heart implant and a more cautious outlook for the back half of the year. (Reuters)
Heightened competition in the U.S. electrophysiology market has led to market share losses for Boston Scientific and is expected to persist into 2027, weighing on its core cardiovascular segment’s growth trajectory. (Reuters)
The company trimmed its full-year organic net sales growth outlook to 5.5%–6.5%, down from a prior range of 6.5%–8%, indicating a deceleration in underlying sales momentum. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 21 Aug 2026.
BSX Financial Performance
Revenues and expenses
BSX Earnings Performance
Company profitability
Upcoming events
No upcoming events
BSX News
AllArticlesVideos
Boston Scientific Stock Slides After Cyberattack Caused ‘Global Disruption'
Investopedia2 weeks ago
Boston Scientific Reports Global Disruption After Cybersecurity Incident
Benzinga2 weeks ago
Medical device maker Boston Scientific says a cyberattack is causing a ‘global disruption' to its operations
TechCrunch2 weeks ago
Funds containing BSX
AllEURGBPUSD
Fund name | Fund size | $BSX weighting |
|---|---|---|
iShares AI Adopters and Applications€AIAA | €169M | 1.41% |
iShares AI Adopters and Applications£AIAA | £145M | 1.41% |
Amundi S&P 500£500G | £6.6B | 1.32% |
iShares Healthcare Innovation$HEAL | $1.4B | 1.27% |
iShares Healthcare Innovation€2B78 | €1.2B | 1.27% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.